Vertex Pharmaceuticals (VRTX) Capital Leases (2011 - 2025)

Vertex Pharmaceuticals' Capital Leases history runs 15 years deep, the most recent figure standing at $111.4 million for Q1 2025.

• In Q1 2025, Capital Leases fell 69.18% year-over-year to $111.4 million; the TTM figure through Mar 2025 stood at $111.4 million (down 69.18% YoY), while the FY2024 annual figure was $112.8 million, down 70.01% from the prior year.
• Capital Leases was $111.4 million for Q1 2025 at Vertex Pharmaceuticals, down from $112.8 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $530.3 million in Q1 2021 to a low of $111.4 million in Q1 2025.
• Historically, Capital Leases has averaged $386.1 million across 5 years, with a median of $417.6 million in 2023.
• The sharpest annual moves came in 2021 and 2024: Capital Leases grew 0.55% in 2021, then sank 70.79% in 2024.
• A 5-year view of Capital Leases shows it stood at $509.8 million in 2021, then fell by 15.5% to $430.8 million in 2022, then decreased by 12.7% to $376.1 million in 2023, then tumbled by 70.01% to $112.8 million in 2024, then slipped by 1.24% to $111.4 million in 2025.
• The last three Capital Leases figures came in at $111.4 million (Q1 2025), $112.8 million (Q4 2024), and $114.0 million (Q3 2024), per Business Quant data.